Dublin, July 03, 2026 (GLOBE NEWSWIRE) — The “Cancer Metabolism Based Therapeutics Market (2nd Edition) by Type of Modality, Route of Administration, Target Disease Indication, Geographical Regions and Sales Forecast of Therapies – Trends and Forecast 2026-2035” has been added to ResearchAndMarkets.com’s offering.
The cancer metabolism-based therapeutics market is anticipated to expand significantly, from an estimated USD 3.7 billion currently to USD 26.3 billion by 2035, reflecting a CAGR of 24.3%. This growth underscores the increasing importance and demand for innovative cancer treatment strategies.
Cancer Metabolism Based Therapeutics Market: Growth and Trends
Cancer remains a critical global health challenge, with millions affected annually. The growth of cancer cells is driven by metabolic reprogramming, enabling them to use nutrients differently than normal cells. This metabolic reprogramming involves changes in key pathways, such as increased glucose absorption, mitochondrial function, and nutrient reliance. The work of Otto Warburg highlighted that tumor tissues prefer aerobic glycolysis, sparking industry interest in targeting these altered metabolic pathways. Research has since aimed at understanding enzymes in pathways like the TCA cycle, lipid biosynthesis, and nucleotide metabolism.
Such insights have promoted the development of cancer metabolism-based therapeutics, which have shown potential in effectively targeting tumor-specific pathways, disrupting uncontrolled proliferation. This has led to numerous strategic collaborations worldwide, expected to bolster market growth as more candidates reach late-stage clinical trials.
Growth Drivers: Strategic Enablers of Market Expansion
The market is driven by the precision medicine approach, focusing on tumor-specific metabolic pathways for personalized and effective treatment strategies. The rise in the global cancer burden, projected to exceed 35 million cases annually by 2050, fuels the demand for these targeted therapies. Such therapies offer improved efficacy and personalization compared to conventional treatments.
Market Challenges: Critical Barriers Impeding Progress
The market faces challenges, including specificity issues and metabolic pathway complexities in tumors. Existing therapies often suffer from limited target specificity and toxicity, affecting clinical trial success and commercial viability. Cancer cells’ metabolic plasticity complicates targeting efforts, emphasizing the need for personalized approaches in oncology.
Cancer Metabolism Based Therapeutics Market: Key Insights
- Approximately 250 therapeutic programs target cancer metabolism vulnerabilities, with nearly 90% in clinical stages, many in phase II trials.
- Increased strategic collaborations, especially in the last two years, have seen over 50% of deals from North America.
- Rising cancer prevalence and advancements in research are driving market growth at a CAGR of 24.3% till 2035.
Market Segmentation Analysis
The report details market segmentation by types such as modality, route of administration, disease indication, geographical regions, and therapy sales forecasts.
Regional Market Analysis: Key Growth Areas
North America is expected to hold over 45% of the market share by 2035, due to strong therapy demand and developer presence. Asia-Pacific is expected to see the fastest growth, driven by burgeoning investments in novel therapies and a burgeoning patient population.
Research Coverage
- Detailed market analysis by modality type, administration route, and regional opportunities.
- Company profiles and development activities in North America, Europe, and Asia-Pacific.
- Analysis of clinical trials and partnership models.
- Identifying key drivers, challenges, and opportunities in the market.
Key Questions Answered in this Report
- Leading companies in the market and their strategies.
- Dominant regional markets and observed key trends.
- Main challenges for developers and how market opportunities are distributed across segments.
Reasons to Buy this Report
- Offers revenue project forecasts and identifies growth prospects.
- Provides insights on market trends, opportunities, and sector-specific customer demand.
- Assists new entrants in strategic planning and market entry.
Additional Benefits
- Complementary Excel data packs and report updates.
- Customizable content and detailed report walkthroughs with research teams.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2026 – 2035 |
| Estimated Market Value (USD) in 2026 | $3.7 Billion |
| Forecasted Market Value (USD) by 2035 | $26.3 Billion |
| Compound Annual Growth Rate | 24.3% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol Myers Squibb
- Eli Lilly
- Novartis
- Polaris
- Roche
For more information about this report visit https://www.researchandmarkets.com/r/r1vedv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Cancer Metabolism Based Therapeutics Market
